Pharmaceutical preparations for treating side effects during and/or after GnRHa therapy
    1.
    发明授权
    Pharmaceutical preparations for treating side effects during and/or after GnRHa therapy 失效
    在GnRHa治疗期间和/或之后治疗副作用的药物制剂

    公开(公告)号:US06689768B2

    公开(公告)日:2004-02-10

    申请号:US09891722

    申请日:2001-06-26

    IPC分类号: A61K3156

    CPC分类号: A61K31/56

    摘要: The pharmaceutical preparations for treating side effects, such as hot flashes, prostate enlargement and gynecomastia, during and/or after treatment with analogs or antagonists of gonadotropin-releasing hormone (GnRHa therapy) contain an effective amount of a chemically modified derivative of 17&agr;-estradiol, a chemically modified derivative of 17&bgr;-estradiol and/or a chemical modified derivative of estriol. Pharmaceutical preparations containing 14&agr;, 15&agr;-methylene-1,3,5(10),8-tetraene-3,17&agr;-diol are particularly preferred.

    摘要翻译: 在用促性腺激素释放激素(GnRHa治疗)的类似物或拮抗剂治疗期间和/或之后用于治疗副作用(例如潮热,前列腺增生和男子乳房发育症)的药物制剂含有有效量的17α-雌二醇的化学修饰衍生物 ,17β-雌二醇的化学改性衍生物和/或雌三醇的化学改性衍生物。 含有14α,15α-亚甲基-1,3,5(10),8-四烯-3,17a-二醇的药物制剂是特别优选的。

    MEANS AND METHODS FOR DIAGNOSING ENDOMETRIOSIS
    3.
    发明申请
    MEANS AND METHODS FOR DIAGNOSING ENDOMETRIOSIS 审中-公开
    用于诊断子宫内膜异位症的手段和方法

    公开(公告)号:US20120190561A1

    公开(公告)日:2012-07-26

    申请号:US13295805

    申请日:2011-11-14

    摘要: The present invention relates to means and methods for diagnosing or predicting endometriosis in a female subject. Particularly, the present invention relates to methods for determining the susceptibility to, predisposition for, presence of and/or risk of developing or suffering from endometriosis in a female subject. The present invention also relates to a kit useful for determining the risk of developing or suffering from endometriosis in a subject, a binding molecule specifically binding to the DBP GC*2 or DBP GC*1 allele product, and a binding molecule binding to the gene encoding the DBP GC*2 or GC*1 allele.

    摘要翻译: 本发明涉及用于诊断或预测女性受试者子宫内膜异位症的方法和方法。 特别地,本发明涉及用于确定女性受试者对子宫内膜异位发展或患有子宫内膜异位症的易感性,易感性和/或风险的方法。 本发明还涉及可用于确定受试者发生或患有子宫内膜异位症的风险的试剂盒,特异性结合DBP GC * 2或DBP GC * 1等位基因产物的结合分子以及与该基因结合的结合分子 编码DBP GC * 2或GC * 1等位基因。

    Method for Diagnosing Preeclampsia
    4.
    发明申请
    Method for Diagnosing Preeclampsia 审中-公开
    诊断先兆子痫的方法

    公开(公告)号:US20140127703A1

    公开(公告)日:2014-05-08

    申请号:US14127934

    申请日:2012-06-28

    IPC分类号: G01N33/68 C12Q1/68

    摘要: Described is a method for in vitro diagnosing whether a pregnant woman has a risk for developing preeclampsia (PE) comprising the steps of determining the afamin content of the pregnant woman in a blood sample or a blood-derived sample, urine, amniotic and cerebrospinal fluid; or determining the content of afamin m-RNA in a liver tissue sample; and comparing the afamin content determined in the sample with a reference value.

    摘要翻译: 描述了一种用于体外诊断怀孕妇女是否有发展先兆子痫(PE)的风险的方法,包括以下步骤:确定血液样本或血液来源的样品,尿液,羊水和脑脊液中孕妇的微量含量 ; 或确定肝脏组织样本中的afamin m-RNA的含量; 并将样品中确定的微量含量与参考值进行比较。